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4 BJN ActivHeal Supplement
Dr Karen Ousey, Reader in Advancing Clinical Practice, 
School of Human and Health Sciences, University of 
Hudderseld
The Department of Health (DH) (2009a; b; 2010a; b) has clearly 
identi!ed the importance of maintaining and developing a quality 
service to all health and social care users. The QIPP agenda; Quality, 
Innovation, Productivity and Prevention relates well to the specialities 
of tissue viability and wound care. Integral to maintaining and 
developing quality is the ethos ‘No decision about me without me’ 
promoted in Equity and Excellence: Liberating the NHS (DH, 2010a) 
that suggests patients should be involved in the decision-making 
process alongside practitioners. Indeed, patients will be in charge of 
making decisions about their care and will be able to choose which 
consultant-led team, general practitioner and treatment they have. 
The patients’ experience and satisfaction will be analysed through 
the use of Patient Reported Outcomes Measures (PROMs) and the 
amount of complaints received by healthcare users. 
The importance of being able to ensure that care administered to 
patients is based on the best available evidence, and is cost effective 
has never been more signi!cant, with the DH (2010a) identifying that 
the NHS must make ef!ciency savings of between £15-£20 billion by 
the end of 2013/14. In relation to tissue viability, Posnett and Franks 
(2008) had calculated that 200 000 people in the UK have a chronic 
wound with an estimated cost of treatment being £2.3–£3.1billion 
per year, these numbers will no doubt rise over the next few years as 
the ageing population increases.
The cost of preventing and treating pressure ulcers in a 600-bed 
acute trust has been estimated as being between £600 000 and 
£3 million a year (Touche, 1993). In 2010 the DH (2010b), estimated 
the cost of a category 3 pressure ulcer as being between £363 000 
to £543 000 and a category 4 pressure ulcer as costing between 
£447 000 and £668 000. They identi!ed that a reduction of 25% in 
pressure ulcers would mean 88 fewer pressure ulcers and a potential 
cost saving of £510 000 in health care per year, per NHS trust. Many 
pressure ulcers are preventable through risk assessment and the 
implementation of pressure-relieving measures with the DH 
promising that there would be ‘safer care for patients, who can be 
con!dent that they will be protected from avoidable harm’ (DH, 
2009a:29). This can only happen if health professionals are provided 
with evidence that supports the use of wound dressings; education 
to develop their own knowledge and the skills to evaluate and 
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AIM OF THE EVALUATION
The overall aim of the series of case studies is to provide clinical 
information on the usability, acceptability and clinical performance of 
the ActivHeal® range of products, when used in the management of 
chronic wounds of various aetiologies. 
understand the results of audit; reliability and validity of evidence and 
research presented to justify the use of wound care products. 
Horkan et al (2009) explored whether or not systematic reviews, 
undertaken during the period 1998-2008, focusing on the issue of 
standard advanced wound dressings, added to the body of 
knowledge in wound dressings. They identi!ed 13 systematic reviews 
and meta-analysis studies concluding that ‘it appears that consistent 
evidence that any one moist wound healing dressing is better than 
another in terms of wound healing is still lacking’ (Horkan et al, 2009: 
304). Nelson and Bradley’s (2007) review of the Cochrane database 
exploring dressings and topical agents for arterial leg ulcers, identi!ed 
that there was no evidence to allow any recommendations to be made 
on the choice of dressing type or topical agent.
A 3-month ‘in-use’ trial of the ActivHeal® dressings was undertaken 
by Lewis (2009) to ascertain the amount of money that could be 
saved if the Trusts’ current choice of wound dressings were replaced 
by those from the ActivHeal® range. ActivHeal® dressings were 
evaluated on care of older people, surgical, orthopaedic and 
neurology wards replacing the current foam, alginate, gel and 
hydrocolloid dressings on the chosen wards. At each dressing 
change, the nurse was required to !ll out an evaluation form, at the 
end of one calendar month the completed evaluation forms were 
collected and each product was given an evaluation result as being 
either ‘worse than’, ‘equivalent to’, or ‘better than’ the previously 
used dressing. In terms of dressing performance, there was no 
obvious difference between the original ‘branded’ dressings and the 
replacement ActivHeal® range. The ActivHeal® dressings were rated 
as ‘equivalent to’ or ‘better than’ original dressings in almost all 
cases. The nursing staff registered no complaints about the change 
to the ActivHeal® range of dressings.
Following completion of the trial Lewis estimated that the annual cost 
saving on foam dressings alone was in excess of £41 000. The annual 
spend on wound dressings, prior to using ActivHeal®, was £103 029, 
the equivalent of 3 month spend, when using ActivHeal® range was 
£11 952 which equated to an annual spend of £47 808. Lewis 
acknowledges that this trial was only run over a limited period of time 
and therefore the !ndings may not be as accurate as a longer trial.
This supplement presents a series of case studies using the 
ActivHeal® range of products; foam non-adhesive; foam adhesive; 
alginate; aqua!ber; hydrocolloid and hydrogel dressings. The 
methodology and patient sample will be expanded in the 
methodology section. The case studies highlight and discuss the use 
of the product range and the results that were experienced by the 
practitioners and patients. A variety of wounds were used to evaluate 
the product range with results showing that the products worked 
effectively; were cost effective; comfortable to the patient; easy to 
use and caused little discomfort on removal. 
In the current health economic climate, cost savings are essential for 
each health professional and commissioner, without reducing the 
quality of care offered to each patient. The case studies presented in 
this booklet discuss, highlight and present a range of dressings that 
can provide a cost-effective dressing range that are evaluated by 
practitioners and patients positively. 
It is the aim of this series of evaluations to show progression of 
healing in all cases, irrespective of the healing variables and the 
setting of care.
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METHODOLOGY SUMMARY
The evaluation reviewed the use of the ActivHeal® dressings in 
up to 11 patients per product section. Patients were recruited 
for the evaluation from the adult (>18 years) population who 
were routinely seen by the evaluating clinicians. The results 
were based on subjective data collected by the clinicians who 
took part in the evaluation.
Patients were included on the basis of having a wound that was 
suited to the product in accordance with the indications and 
contraindications in the ‘ instruction for use’ lea#et for each product.
The decision to treat the patient with the ActivHeal® dressing was 
made before the patient was considered for inclusion in the evaluation 
and following a full wound assessment. The patients’ care was not 
affected and the wound dressing chosen was the most suitable 
following the patients’ assessment. The Trust’s standard practice of 
patient assessment and treatment was followed throughout the 
evaluation. Each dressing was applied and changed following a 
wound assessment by the registered practitioner and as required by 
the patient’s need or as dictated by the level of exudate, maintaining 
good wound care practice according to the Trust’s standard of 
practice. The ActivHeal® dressing was used as a primary or secondary 
dressing to suit the wound variables and in accordance with Trust 
policy. Table 1 provides guidance on which ActivHeal® dressings are 
appropriate for each wound type
Consent was given by patients before inclusion within the evaluation. 
Consent was also gained to have photographs taken and published. 
No further ethical approval was required as the use of the product 
was classed as an evaluation.
The assessment of the ActivHeal® products were conducted in the 
form of a series of evaluations that included dressing changes. The 
evaluations were completed by the relevant tissue viability nurse who 
attended the patient at each dressing change. During each dressing 
change the tissue viability nurse consulted with the attending nurse 
and patient regarding the progression of the wound; amount of 
exudate, level of pain experienced during dressing change and the 
ease of use of each dressing. The assessment of the wound was 
documented using data collection and evaluation forms provided by 
Advanced Medical Solutions Ltd. This enabled the data gathered to 
be collated to provide clinical evidence relating to the use and 
performance of the ActivHeal® dressing range in clinical practice; 
progression of the wound and the achievement of patient outcomes. 
The patient was also asked to give their opinion on how the dressing 
felt throughout its weartime and if it caused any discomfort on 
removal. Their comments were noted throughout the data collection.
The evaluation parameters/considerations that were applied are:
• Ability to manage exudate
• Conformability
• Maintaining moist wound environment
• Ease of use
• Overall rating
• Assessment of wound bed/wound progression.
Wound type Clinical considerations Expected outcomes
Product category 
(primary dressing)
ActivHeal® product
Case study page 
reference 
Necrotic
If clinically relevant, 
removal of necrotic 
tissue – barrier to 
healing
Clean, viable wound 
bed free of necrotic 
tissue
Hydrogel ActivHeal® Hydrogel 14
Sloughy
Removal of sloughy 
tissue – barrier to 
healing
Clean, viable wound 
bed free of sloughy 
tissue
Hydrocolloid, 
Alginate, 
Aqua!ber
ActivHeal® Alginate, 
ActivHeal Aqua!ber® 
ActivHeal®Hydrocolloid, 
7, 8, 12
Highly exuding
Manage excess 
exudate. Identify cause 
of excess exudate 
Exudate could macerate 
peri-wound area
Reduction in exudate 
volume
Foam, Alginate, 
Aqua!ber
ActivHeal® Alginate, 
ActivHeal Aqua!ber® 
ActivHeal® Foam
7, 8, 10
Granulating
Protect the fragile 
granulating tissue 
Stimulate growth
Healthy looking 
granulating tissue 
Epithelialising wound
Foam ActivHeal® Foam
10
Epithelialising 
Maintain and protect 
epithelial tissue
Healed wound Hydrocolloid ActivHeal® Hydrocolloid 12
Table 1: Appropriate dressing selection when considering ActivHeal® wound care range
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